A pivotal study comparing adalimumab and ustekinumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease was published on 2022-01-01. This multicenter trial, known as SEAVUE, investigated the safety and efficacy of these two biologics over one year.
Background
Adalimumab (Humira, Hulio, Yusimry, Yuflyma, Idacio, Simlandi, Amjevita, Cyltezo, Hadlima, Hyrimoz, and others) is a widely used biologic medication. This study focused on its use in moderately to severely active Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract. The trial compared adalimumab against ustekinumab, another established biologic, in patients who had not previously received biologic therapy.
Trial design
The SEAVUE study was a multicenter trial designed to compare ustekinumab versus adalimumab. It investigated these treatments for both induction and maintenance therapy. The patient population included biologic-naive individuals with moderately to severely active Crohn's disease. The study aimed to assess the safety and efficacy of both drugs over a period of one year.
What this means
The publication of the SEAVUE study provides important comparative data for clinicians treating moderately to severely active Crohn's disease. By directly comparing adalimumab and ustekinumab in biologic-naive patients, the study contributes to understanding the relative performance of these two established biologics for both induction and maintenance therapy over one year. While specific outcomes are not detailed in the provided data, the study's focus on safety and efficacy in a head-to-head comparison offers valuable insights for treatment selection in this patient population.
Source
The information regarding this pivotal study was published on 2022-01-01. The source is PubMed, a database of biomedical literature, and the article can be accessed via pubmed.ncbi.nlm.nih.gov.